GlobalData
GlobalData

Sarath.Chandra@globaldata.com

  • Home
  • Author: Sarath.Chandra@globaldata.com

Lilly donanemab flaunts strong clinical profile in data read-out, ready to compete with Leqembi if approved, says GlobalData

Following the news that Eli Lilly published full results from its TRAILBLAZER-ALZ 2 (NCT04437511) study of anti-amyloid-beta (Aβ) monoclonal antibody (mAb), donanemab, in Alzheimer’s disease (AD); Rose Joachim, Director of Neurology at GlobalData, a leading data and analytics company, offers her view: “On the heels of the US FDA’s approval of Eisai and Biogen’s Leqembi […]
Read more

GenAI revolutionizes customer communication channels in retail, says GlobalData

From revolutionizing the nuts and bolts of supply chain operations to turbo-charging customer service, generative artificial intelligence (genAI) stands on the forefront of innovation in retail. Its ability to fabricate hyper-customized content is turning the tables in marketing and communication strategies, says GlobalData, a leading data and analytics company. Kiran Raj, Practice Head of Disruptive […]
Read more

Chile real GDP to contract in 2023, forecasts GlobalData

The economy of Chile is expected to face several challenges in 2023, including lower copper production, fluctuations in commodity prices, high inflationary pressures, strict monetary policies, and low business confidence. These factors are likely to have a dampening effect on investments and domestic demand, resulting in subdued economic activities. Additionally, the global economic slowdown is […]
Read more

China in-house R&D paves way for improved access to KRAS G12C inhibitors for NSCLC, says GlobalData

China is emerging as a key player in developing novel oncology therapies, particularly in treating non-small cell lung cancer (NSCLC). Kirsten rat sarcoma homolog (KRAS) G12C inhibitors have gained significant attention for their efficacy in targeting KRAS G12C mutations, prevalent in NSCLC. China’s robust pipeline of in-house developed therapies targeting these mutations promises future affordability […]
Read more

Average premium earned by top 20 global public insurers up by 3.3% in 2022, reveals GlobalData

The top global public insurance companies sustained their momentum in 2022, benefiting from increased insurance awareness following the COVID-19 pandemic and an economic rebound in most global markets. The average premium earned* of the top 20 global insurers grew by 3.3% while experiencing a slight 2.3% decline in total revenue, reveals GlobalData, a leading data […]
Read more

15 of top 20 biopharmaceutical companies by revenue report 5.2% YoY growth in 2022, reveals GlobalData

The biopharmaceutical industry had an exceptional year in 2022 with notable success for those with COVID-19 vaccines. The majority (15) of the top 20 publicly traded global innovative biopharmaceutical companies reported a 5.2% growth in the aggregate revenue to $868.97 billion from 2021 to 2022, reveals GlobalData, a leading data and analytics company.   GlobalData […]
Read more

China success story in homegrown CAR-T therapies development continues with Fucaso approval, says GlobalData

The National Medical Products Administration (NMPA) has recently approved Innovent Biologics and IASO Bio’s CAR-T therapy equecabtagene autoleucel (Fucaso) for the treatment of relapsed and/or refractory multiple myeloma (R/R MM). It will be the first CAR-T therapy for MM patients and second one by a homegrown company in China. The approval will further boost CAR-T […]
Read more

Ripple Labs win over SEC sparks crypto market surge and paves way for industry shift, says GlobalData

Following the news that Ripple Labs has won a case against the US Securities and Exchange Commission (SEC); Nicklas Nilsson, Thematic Intelligence Consultant at GlobalData, offers his view: “The US judge ruled that the open market sales of XRP, Ripple’s cryptocurrency developed for cross-border payments, do not classify as a security. The ruling will have […]
Read more
1 … 98 99 100 101 102 … 209